Skip to main content
Journal cover image

Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.

Publication ,  Journal Article
Hosein, PJ; Sandoval-Sus, JD; Goodman, D; Arteaga, AG; Reis, I; Hoffman, J; Stefanovic, A; Rosenblatt, JD; Lossos, IS
Published in: Am J Hematol
June 2015

A phase II trial of R-MACLO-IVAM followed by thalidomide maintenance for mantle cell lymphoma (MCL) demonstrated promising progression-free survival (PFS) and overall survival (OS) rates. Thalidomide maintenance was associated with significant toxicity and was subsequently modified to rituximab maintenance. Herein, we present updated results and follow-up. Two sequential phase II trials included chemotherapy-naïve patients with MCL up to 75 years old. Four cycles of R-MACLO-IVAM chemotherapy were delivered as previously described. Patients who achieved complete responses (CR) were eligible for thalidomide or rituximab maintenance therapy. Among 36 patients enrolled, the MCL International Prognostic Index (MIPI) was low in 53%, intermediate in 36% and high in 11%. Thirty-five patients completed at least 2 cycles of chemotherapy; 34 (94%) achieved a CR. After a median follow-up of 74.4 months, the 5-year PFS was 51% (95% CI 33-68%) and the 5-year OS was 85% (95% CI 73-97%). Two deaths occurred during the chemotherapy phase due to disease progression and neutropenic sepsis, respectively. One patient developed secondary acute myeloid leukemia after 7 years. R-MACLO-IVAM chemotherapy is effective for patients with newly diagnosed MCL.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Hematol

DOI

EISSN

1096-8652

Publication Date

June 2015

Volume

90

Issue

6

Start / End Page

E111 / E116

Location

United States

Related Subject Headings

  • Thalidomide
  • Survival Rate
  • Survival Analysis
  • Rituximab
  • Prospective Studies
  • Middle Aged
  • Male
  • Lymphoma, Mantle-Cell
  • Immunology
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hosein, P. J., Sandoval-Sus, J. D., Goodman, D., Arteaga, A. G., Reis, I., Hoffman, J., … Lossos, I. S. (2015). Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma. Am J Hematol, 90(6), E111–E116. https://doi.org/10.1002/ajh.23996
Hosein, Peter J., Jose D. Sandoval-Sus, Deborah Goodman, Alexandra Gomez Arteaga, Isildinha Reis, James Hoffman, Alexandra Stefanovic, Joseph D. Rosenblatt, and Izidore S. Lossos. “Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.Am J Hematol 90, no. 6 (June 2015): E111–16. https://doi.org/10.1002/ajh.23996.
Hosein PJ, Sandoval-Sus JD, Goodman D, Arteaga AG, Reis I, Hoffman J, et al. Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma. Am J Hematol. 2015 Jun;90(6):E111–6.
Hosein, Peter J., et al. “Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.Am J Hematol, vol. 90, no. 6, June 2015, pp. E111–16. Pubmed, doi:10.1002/ajh.23996.
Hosein PJ, Sandoval-Sus JD, Goodman D, Arteaga AG, Reis I, Hoffman J, Stefanovic A, Rosenblatt JD, Lossos IS. Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma. Am J Hematol. 2015 Jun;90(6):E111–E116.
Journal cover image

Published In

Am J Hematol

DOI

EISSN

1096-8652

Publication Date

June 2015

Volume

90

Issue

6

Start / End Page

E111 / E116

Location

United States

Related Subject Headings

  • Thalidomide
  • Survival Rate
  • Survival Analysis
  • Rituximab
  • Prospective Studies
  • Middle Aged
  • Male
  • Lymphoma, Mantle-Cell
  • Immunology
  • Humans